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behavioral therapy, life style modiﬁcation and medical treatment
with antimuscarinics.1 In patientswho fail the second line treatment,
electrical stimulation or surgical therapymight be the rescuemodal-
ity. Although these treatments are effective in relief of urgency and
urgency urinary incontinence in about 70% of OAB patients, around
30% of patients are still with inadequate treatment and poor quality
of life and only about 30% of themcan adhere to antimuscarinic treat-
ment.2,3 In patients who fail the ﬁrst antimuscarinic therapy, adding
a second antimuscarinic agentmight be effective in>30% of patients;
however, intolerable averse events and large postvoid residual (PVR)
remainproblems to be solved.4 It ismandatory to have a guideline for
physicians to follow for the treatment for OAB refractory to conven-
tional therapy. In this issue, Wang et al5 proposed the guidelines for
adult patients with OAB. It is the ﬁrst OAB guideline for Taiwanese
physicians and patients to follow.
In recent decades, intravesical botulinum toxin A (BoNT-A) injec-
tion has beenwidely used to decrease urgency or urgency urinary in-
continence in OAB patients.6,7 BoNT-A injection has been found to
decrease sensory receptors such as P2X3 and TRPV1 in suburothelial
nerve ﬁbers, which results in reduction of sensory urgency and
decrease in detrusor contractility.8 Currently, 100 U BoNT-A injection
has been approved to use in refractory OAB patients in the USA,
Europe, and many Asian countries and has been shown to improve
the quality of life of patients.9,10 Although BoNT-A injection may in-
crease PVR and the incidence of urinary tract infection, the reduction
of urgency severity was associated with an improved satisfactory
outcome.11 After the 1st month after BoNT-A injection, patients
may enjoy an improved quality of life. However, before we recom-
mend this treatment to refractory OABpatients, careful patient selec-
tion and informed consent are extremely important to avoid
unexpected adverse events and patients dissatisfaction.
Mirabegron, a b3-adrenoceptor agonist, is a new class drug for
the treatment of OAB. The mechanism of b3-adrenoceptor is
different from antimuscarinic agents. Concerning the Adverse
events (AE) with antimuscarinic drugs, the pooled safety data indi-
cate that mirabegron may be a valuable treatment option for pa-
tients with OAB.12 Animal study and clinical urodynamic study
have shown that detrusor contractility does not decrease after mir-
abegron treatment.13 In this issue, Kuei et al14 review the recent ad-
vances in therapeutic application of mirabegron on OAB. Another
Taiwanese clinical trial (Clinical trial. gov. ID: NCT01043666) of mir-
abegron has demonstrated that the daily frequency episode can be
reduced after mirabegron therapy and no clinically relevant
adverse events were identiﬁed in OAB patients. The results of this
clinical trial are similar to that reported in the USA, Europe, and
Japan.15e17 Given that dry mouth and dysuria are the chief causehttp://dx.doi.org/10.1016/j.urols.2014.12.002
1879-5226/Copyright © 2014, Taiwan Urological Association. Published by Elsevier Taiwof discontinuation of antimuscarinics because of poor tolerability,
mirabegron has been considered as a potentially ﬁrst line medical
treatment for OAB patients.
Intravesical administration of liposomes into the wounded uro-
theliummay improve the dysfunctional urothelium and provide an
alternative treatment for interstitial cystitis/bladder pain syn-
drome. In addition, in rat models of hypersensitive bladder, intra-
vesical instillation of liposomes could reduce the bladder
hypersensitivity induced by intravesical potassium chloride or ace-
tic acid without compromise of voiding function.18 One pilot study
has demonstrated that intravesical lipotoxin instillation can effec-
tively reduce frequency and urgency episodes 1 month after treat-
ment in OAB patients. The PVR did not increase, and all patients
were free of urinary tract infection after the treatment.19 Another
two-center, double-blind, randomized, placebo controlled study
enrolled patients with OAB who were inadequately managed by
antimuscarinics.20 At Week 4 after treatment, lipotoxin signiﬁ-
cantly decreased total frequency per 3 days. Total urgency and over-
active bladder symptom score also signiﬁcantly decreased in the
lipotoxin group. These results support that BoNT-A delivered by li-
posomes might be lower than with injection; thus the therapeutic
effects might be limited to the urothelial sensory nerves without
compromise to detrusor contractility. Hung et al,21 in this issue, re-
view the clinical application of liposomes and lipotoxin in lower
urinary tract dysfunction. The clinical results of lipotoxin in the
treatment of interstitial cystitis/bladder pain syndrome and OAB
support the liposomes as an efﬁcient vehicle for delivering of
BoNT-A without the need for injection.
In conclusion,we can see a change of the promised treatmentmo-
dalities of OAB,whichmoves toward amore effective and safer future
to our patients. Mirabegron may become the ﬁrst line medication
treatment for OAB. If inadequate, adding antimuscarinic agent at a
small dose may provide efﬁcient results. For patients with OAB and
undesired adverse events after antimuscarinic therapy, intravesical
liposomes encapsulated BoNT-A might be a suitable treatment.
Finally, in patients with OAB refractory to all kinds of treatments,
intravesical BoNT-A injection may be the last treatment.
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